4 research outputs found
Differences in Leadership Styles between Genders: Outcomes and Effectiveness of Women in Leadership Roles
Women, today constituting a large portion of the work force have very few leaders at the top constitutional or organizational positions. In this paper we try to analyze what’s causing hindrance to their growth focusing primarily, if there exists any differences in the leadership styles employed by male and female leaders. As was the case in previous literature, the evidence for sex differences in leadership behavior is still mixed, yet it is clear that these sex differences have not vanished. It is argued that sex differences in leadership styles are largely a consequence of the context in which male and female leaders work. Arguments and evidences from both sides on, “Do women really make better androgynous leaders?” is analyzed overall based on several inferences. This paper further focuses on the values and attitudes of women being in leadership positions leaving challenges for further research on the effect of external variables such as the work force, corporation structure, and necessity of innovation on the gender in the leadership role
Recommended from our members
Lymphatic endothelial S1P promotes naĂŻve T cell mitochondrial function and survival
Recommended from our members
Engineering an inhibitor-resistant human CSF1R variant for microglia replacement
Hematopoietic stem cell transplantation (HSCT) can replace endogenous microglia with circulation-derived macrophages but has high mortality. To mitigate the risks of HSCT and expand the potential for microglia replacement, we engineered an inhibitor-resistant CSF1R that enables robust microglia replacement. A glycine to alanine substitution at position 795 of human CSF1R (G795A) confers resistance to multiple CSF1R inhibitors, including PLX3397 and PLX5622. Biochemical and cell-based assays show no discernable gain or loss of function. G795A- but not wildtype-CSF1R expressing macrophages efficiently engraft the brain of PLX3397-treated mice and persist after cessation of inhibitor treatment. To gauge translational potential, we CRISPR engineered human-induced pluripotent stem cell-derived microglia (iMG) to express G795A. Xenotransplantation studies demonstrate that G795A-iMG exhibit nearly identical gene expression to wildtype iMG, respond to inflammatory stimuli, and progressively expand in the presence of PLX3397, replacing endogenous microglia to fully occupy the brain. In sum, we engineered a human CSF1R variant that enables nontoxic, cell type, and tissue-specific replacement of microglia
Lymphatic endothelial S1P promotes mitochondrial function and survival in naive T cells
Effective adaptive immune responses require a large repertoire of naive T cells that migrate throughout the body, rapidly identifying almost any foreign peptide. Because the production of T cells declines with age, naive T cells must be long-lived. However, it remains unclear how naive T cells survive for years while constantly travelling. The chemoattractant sphingosine 1-phosphate (S1P) guides T cell circulation among secondary lymphoid organs, including spleen, lymph nodes and Peyer's patches, where T cells search for antigens. The concentration of S1P is higher in circulatory fluids than in lymphoid organs, and the S1P1 receptor (S1P1R) directs the exit of T cells from the spleen into blood, and from lymph nodes and Peyer's patches into lymph. Here we show that S1P is essential not only for the circulation of naive T cells, but also for their survival. Using transgenic mouse models, we demonstrate that lymphatic endothelial cells support the survival of T cells by secreting S1P via the transporter SPNS2, that this S1P signals through S1P1R on T cells, and that the requirement for S1P1R is independent of the established role of the receptor in guiding exit from lymph nodes. S1P signalling maintains the mitochondrial content of naive T cells, providing cells with the energy to continue their constant migration. The S1P signalling pathway is being targeted therapeutically to inhibit autoreactive T cell trafficking, and these findings suggest that it may be possible simultaneously to target autoreactive or malignant cell survival